SUNITINIB
sunitinib 12.5 mg capsule, 28
SUNITINIB (10004M)
10004M
Manner of administration:Oral
Restriction
Indication: Metastatic or unresectable, well-differentiated malignant pancreatic neuroendocrine
tumour (pNET)
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 28 | # of repeats: 2 | DPMQ: $524.33 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||
|
|
|||||